Condition: Agitation · Alzheimer Disease · Sponsor: Celgene
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| Local Institution - 0046 | Homewood, Alabama, United States | Not Yet Recruiting |
| University of Alabama - Huntsville Regional Medical Campus | Huntsville, Alabama, United States | Recruiting |
| Local Institution - 0048 | Phoenix, Arizona, United States | Completed |
| Local Institution - 0040 | Scottsdale, Arizona, United States | Not Yet Recruiting |
| Local Institution - 0017 | Anaheim, California, United States | Not Yet Recruiting |
| Inland Psychiatric Medical Group. | Chino, California, United States | Recruiting |
| Kaizen Brain Center | La Jolla, California, United States | Recruiting |
| University of California San Diego - La Jolla | La Jolla, California, United States | Recruiting |
| Shreenath Clinical Service - Lakewood | Lakewood, California, United States | Recruiting |
| Accellacare - Sherman Oaks | Sherman Oaks, California, United States | Recruiting |
| Next Level Clinical Trials | West Covina, California, United States | Recruiting |
| Local Institution - 0028 | West Hills, California, United States | Completed |
+ 41 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06808984